Core Viewpoint - Anhui Huaren Health Pharmaceutical Co., Ltd. has approved a proposal to expand its business scope and amend its articles of association, which will be submitted to the shareholders' meeting for review [1][5]. Business Scope Changes - The company plans to add various business activities, including but not limited to: drug wholesale, drug consignment production, internet information services for drugs, food sales, third-class medical device operations, and urban delivery services [2][4]. - The new business scope will also include sales of various products such as infant formula, daily necessities, cosmetics, and electronic products, among others [2][4]. Articles of Association Amendments - The amendments to the articles of association will reflect the expanded business scope, with specific changes to the relevant sections detailing the new permitted activities [3][4]. - Other provisions in the articles of association will remain unchanged, and the board of directors will seek authorization from the shareholders to handle the necessary registration changes [4][5].

Core Viewpoint - Anhui Huaren Health Pharmaceutical Co., Ltd. plans to use up to 100 million yuan of idle raised funds to temporarily supplement working capital, ensuring that it does not affect the construction of fundraising projects and the normal use of raised funds [1][4][5] Summary by Sections Fundraising Basic Information - The company has issued 60.01 million shares at a price of 16.24 yuan per share, raising a total of approximately 974.56 million yuan, with a net amount of 879.45 million yuan after deducting issuance costs [1][2] Fundraising Investment Project Overview - The total investment amount for the fundraising projects is 605.68 million yuan, with the entire amount allocated from the raised funds [2] - The company has decided to change part of the fundraising purpose, allocating 45 million yuan for the "Marketing Network Construction Project" and for acquiring 60% of the shares of Zhoushan Likang Pharmaceutical Chain Co., Ltd. [2] Previous Use of Idle Funds - The company previously used 150 million yuan of idle funds to supplement working capital, which has been fully returned to the fundraising account by May 8, 2025 [4] Current Use of Idle Funds - The company plans to use up to 100 million yuan of idle funds for working capital, with a usage period not exceeding 12 months from the board's approval date [4][5] - The use of these funds is limited to operations related to the main business and cannot be used for stock trading or other financial instruments [5] Necessity and Reasonableness - The decision to use idle funds is aimed at improving fund efficiency, reducing financial costs, and supporting the company's operational needs, thereby enhancing its competitive position in the pharmaceutical health sector [5][6] Review Procedures and Opinions - The board of directors, supervisory board, and independent directors have all approved the use of idle funds, confirming that the process complies with relevant regulations and does not affect the implementation of fundraising projects [6][7]

Core Points - Anhui Huaren Health Pharmaceutical Co., Ltd. is established as a joint-stock company in accordance with the Company Law and other relevant regulations [3][4] - The company was approved by the Shenzhen Stock Exchange and registered with the China Securities Regulatory Commission, issuing 60.01 million shares to the public on March 1, 2023 [3][4] - The registered capital of the company is RMB 400.01 million [3][4] Chapter Summaries General Provisions - The company aims to protect the legal rights of shareholders and creditors while regulating its organization and behavior [3] - The company is located in Hefei, Anhui Province, with a unified social credit code [3][4] - The company is a permanent joint-stock company, and its articles of association are legally binding [3][4] Business Objectives and Scope - The company's business objectives emphasize quality and integrity [3] - The business scope includes pharmaceutical wholesale, medical device sales, food sales, and various consulting services [3][4] Shares - The company's shares are issued in the form of stocks, with equal rights for each type of share [4][5] - The total number of shares is 400.01 million, all of which are ordinary shares [5][6] Shareholder Rights and Responsibilities - Shareholders have the right to receive dividends and participate in decision-making processes [12][13] - Shareholders must comply with laws and the company's articles of association, and they cannot transfer shares within the first year of the company's establishment [12][13] Shareholder Meetings - The company holds annual and temporary shareholder meetings, with specific procedures for convening and voting [17][18] - Shareholders holding more than 10% of shares can request a temporary meeting [18][19] Voting and Resolutions - Resolutions can be classified as ordinary or special, with different voting thresholds required for approval [34][35] - Ordinary resolutions require more than half of the voting rights, while special resolutions require two-thirds [34][35]

Core Viewpoint - The company plans to temporarily use idle raised funds to supplement working capital, ensuring that it does not affect the construction of fundraising projects and normal use of funds [6][11]. Fundraising Basic Situation - The company was approved to issue 60.01 million A-shares at a price of 16.24 yuan per share, raising a total of approximately 974.56 million yuan [1]. - The net amount raised after deducting issuance costs was approximately 879.45 million yuan, with excess funds amounting to approximately 273.77 million yuan [3]. Fundraising Investment Project Basic Situation - The total investment amount for the projects is approximately 605.68 million yuan, all of which is funded by the raised funds [3]. - The company has approved a change in the use of part of the raised funds, allocating 45 million yuan for the "Marketing Network Construction Project" to acquire 60% of the shares in Zhoushan Likang Pharmaceutical Chain Co., Ltd. [4]. Previous Use of Idle Raised Funds - The company previously used 150 million yuan of idle raised funds to supplement working capital, which has been fully returned to the fundraising account within the stipulated period [6][11]. Current Use of Idle Raised Funds - The company plans to use up to 100 million yuan of idle raised funds temporarily to supplement working capital, with a usage period not exceeding 12 months [6][7]. - This use is limited to operations related to the main business and will not be used for stock trading or other non-operational purposes [7]. Necessity and Reasonableness - The decision to use idle funds is aimed at reducing financial costs and supporting the company's operational needs, thereby enhancing its competitiveness in the pharmaceutical health sector [7][9]. Internal Decision-Making Procedures - The board of directors, supervisory board, and independent directors have all approved the use of idle funds, confirming compliance with relevant regulations [8][9][11].

二、监事会会议审议情况 本次会议审议并通过如下议案： 经审议，监事会认为：董事会审议本次变更募集资金用途的程序符合《上市 公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》等中国证监 会和深圳证券交易所规范性文件及公司《公司章程》《募集资金管理制度》等的 相关规定，公司本次变更部分募集资金用途事项，符合公司当前实际和发展需要， 有利于提高募集资金使用效率和长远利益，符合公司及全体股东的利益，不存在 损害公司、投资者特别是中小投资者利益的情形。 本议案尚需提交股东大会审议。 证券代码：301408 证券简称：华人健康 公告编号：2025-041 安徽华人健康医药股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 安徽华人健康医药股份有限公司（以下简称"公司"）第五届监事会第八次 会议已于 2025 年 5 月 16 日以书面、邮件送达形式发出通知，并于 2025 年 5 月 合相关法律法规及《公司章程》的规定，做出的决议合法有效。 经审议，监事会认为：本次使用闲置募集资金临时补充流动资金的审议程序 符合《上市公司监 ...

核查意见 华泰联合证券有限责任公司 关于安徽华人健康医药股份有限公司使用闲置募集资金临 时补充流动资金的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐人"）作 为安徽华人健康医药股份有限公司（以下简称"华人健康"或"公司"）首次公 开发行股票并在创业板上市持续督导阶段的保荐人，根据《证券发行上市保荐业 务管理办法》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监 管要求》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》及《深圳证券交易所上市公司自 律监管指引第 13 号——保荐业务》等有关规定，对华人健康使用闲置募集资金 临时补充流动资金事项进行了核查，具体核查情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意安徽华人健康医药股份有限公司首次 公开发行股票注册的批复》（证监许可[2022]2406 号）同意注册，公司获准向社 会公众发行人民币普通股 A 股 6,001.00 万股，每股面值人民币 1 元。截至 2023 年 3 月 1 日止，公司已向社会公众发行人民币普通股 A 股 6,001 ...

核查意见 华泰联合证券有限责任公司 关于安徽华人健康医药股份有限公司 变更募集资金用途的核查意见 经中国证券监督管理委员会《关于同意安徽华人健康医药股份有限公司首次 公开发行股票注册的批复》（证监许可[2022]2406 号）的同意注册，公司获准向 社会公众发行人民币普通股 A 股 6,001.00 万股，每股面值人民币 1 元。截至 2023 年 3 月 1 日止，公司已向社会公众发行人民币普通股 A 股 6,001.00 万股，每股 发行价格 16.24 元，募集资金总额为人民币 974,562,400.00 元。扣除承销费等发 行费用（不含本次公开发行股票发行费用可抵扣增值税进项税额）人民币 95,110,299.14 元，公司募集资金净额为人民币 879,452,100.86 元。上述资金已于 2023 年 2 月 24 日全部到位，经中天运会计师事务所（特殊普通合伙）审验并出 具中天运[2023]验字第 90009 号《验资报告》。 （二）募集资金的使用情况 华泰联合证券有限责任公司（以下简称"华泰联合证券""保荐人"或"保 荐机构"）作为安徽华人健康医药股份有限公司（以下简称"华人健康""公司" ...

安徽华人健康医药股份有限公司 章程 （本章程经 2025 年第一次临时股东大会审议通过后生效） 二零二五年五月 | | | | 第一章 | 总则 3 | | --- | --- | | 第二章 | 经营宗旨和范围 4 | | 第三章 | 股份 4 | | 第四章 | 股东和股东大会 7 | | 第五章 | 董事会 21 | | 第六章 | 总经理及其他高级管理人员 29 | | 第七章 | 监事会 31 | | 第八章 | 财务会计制度、利润分配和审计 33 | | 第九章 | 通知和公告 37 | | 第十章 | 合并、分立、增资、减资、解散和清算 38 | | 第十一章 | 公司的党组织建设 41 | | 第十二章 | 修改章程 41 | | 第十三章 | 附则 42 | 第一章 总则 公司由安徽省华仁医药经营有限公司以整体变更方式设立，在合肥市市 场监督管理局注册登记，取得营业执照，统一社会信用代码为 91340100730002825G。 第一条 为维护安徽华人健康医药股份有限公司（以下简称"公司"或"本公司"）、 股东和债权人的合法权益，规范公司的组织和行为，根据《中华人民共 和国公司法》（以下简称 ...

证券代码：301408 证券简称：华人健康 公告编号：2025-036 安徽华人健康医药股份有限公司 关于变更募集资金用途的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 安徽华人健康医药股份有限公司（以下简称"公司"或"华人健康"或"上 市公司"）于2025年5月19日召开的第五届董事会第九次会议和第五届监事会第 八次会议，审议通过了《关于变更募集资金用途的议案》，同意公司结合现阶段 发展需求及公司整体经营发展布局等实际情况变更部分募集资金用途。现将具体 情况公告如下： 根据《安徽华人健康医药股份有限公司首次公开发行股票并在创业板上市招 股说明书》，募集资金投资项目及募集资金使用计划如下： | 序号 | 项目名称 | 投资总额（ | 募集资金投资额 | 项目实施周 | 项目实施主 | | --- | --- | --- | --- | --- | --- | | | | 万元） | （万元） | 期 | 体 | | 1 | 营销网络建设项目 | 55,567.80 | 55,567.80 | 36个月 | 安徽国胜等 子公司 | | 2 | 补充流动资金 ...

证券代码：301408 证券简称：华人健康 公告编号：2025-035 安徽华人健康医药股份有限公司 关于收购福建、浙江三家医药连锁公司股权的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、安徽华人健康医药股份有限公司（以下简称"华人健康"或"公司"或 "受让方"）拟通过支付现金方式购买宁波闽哲汇投资合伙企业（有限合伙）(以 下简称"闽哲汇"或"交易对方"或"转让方"）持有的福建省扬祖惠民医药连 锁有限公司（以下简称"扬祖惠民"或"目标公司一"）46.01%的股权、购买闽 哲汇持有的福建海华医药连锁有限公司（以下简称"海华医药"或"目标公司二"） 46.01%的股权及购买闽哲汇持有的桐庐怡生堂大药房连锁有限公司（以下简称 "桐庐怡生堂"或"目标公司三"）70.01%的股权（以下合称"本次交易"或"本 次收购"）。本次交易，公司计划使用自有资金及变更部分募集资金用途进行支 付，若变更募集资金用途的审核未获批准，公司将全部使用自有资金支付。 2、目标公司交接整合期及后期实际经营管理过程中可能受行业政策、营运 管理等方面的影响，从而影响盈利能力。 ...